Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection

Yoshinori Ando1†, Takeshi Noshi1†, Kenji Sato1, Toru Ishibashi2, Yuki Yoshida3, Takahiro Hasegawa4, Motoyasu Onishi1, Mitsutaka Kitano1, Ryoko Oka3, Makoto Kawai1, Ryu Yoshida1, Akihiko Sato1, Takao Shishido1* and Akira Naito1

1Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd, 3-1-1, Futaba-cho, Toyonaka, Osaka 561-0825, Japan; 2Project Management Department, Shionogi & Co., Ltd, 12F, Hankyu Terminal Bldg, 1-4, Shibata 1-chome, Kita-ku, Osaka 530-0012, Japan; 3Data Science Office, Shionogi & Co., Ltd, 12F, Hankyu Terminal Bldg, 1-4, Shibata 1-chome, Kita-ku, Osaka 530-0012, Japan; 4Biostatistics Center, Shionogi & Co., Ltd, 12F, Hankyu Terminal Bldg, 1-4, Shibata 1-chome, Kita-ku, Osaka 530-0012, Japan
*Corresponding author. E-mail: takao.shishido@shionogi.co.jp
†Y. Ando and T. Noshi contributed equally to this work.

Received 10 February 2020; accepted 11 August 2020

Background: Baloxavir acid, the active form of the orally available prodrug baloxavir marboxil, is a novel cap-dependent endonuclease inhibitor of influenza virus. Baloxavir marboxil has been shown to rapidly reduce virus titres compared with oseltamivir in clinical studies.

Objectives: We investigated the relationship between pharmacokinetic (PK) parameters and antiviral activity of baloxavir acid based on virus titre reduction in lungs of infected mice.

Methods: BALB/c mice infected with a sub-lethal dose of influenza A(H1N1), A(H1N1)pdm09, A(H3N2) or type B virus were treated on day 5 with oral baloxavir marboxil (0.5–50 mg/kg q12h), subcutaneous baloxavir acid (0.25–8 mg/kg/day), oseltamivir phosphate (5 or 50 eq mg/kg q12h) or other antivirals for 1 day. Lung virus titres were assessed 24 h after initial antiviral dosing. PK testing was performed at up to 24 h post-dosing of baloxavir marboxil or baloxavir acid in A/WSN/33-infected mice and the PK/pharmacodynamic (PD) relationship was evaluated for baloxavir acid.

Results: Oral baloxavir marboxil administration showed dose-dependent virus titre reductions in lungs of mice infected with the different types/subtypes of influenza viruses 24 h post-dosing. Baloxavir marboxil at 15 mg/kg q12h resulted in ≥100-fold and ≥10-fold reductions in influenza A and B virus titres, respectively, compared with oseltamivir phosphate. PK/PD analysis showed that the plasma concentration at the end of the dosing interval (C_s) or the plasma concentration at 24 h after initial dosing (C_{24}) was the PK parameter predicting the virus titres at 24 h post-dosing of baloxavir acid.

Conclusions: PK/PD analysis of baloxavir acid based on virus titre reduction in this mouse model could be helpful in predicting and maximizing virological outcomes in clinical settings.

Introduction

The influenza virus replicates almost exclusively in epithelial cells of the human upper and lower respiratory tract. Influenza virus replication peaks at approximately 48 h after inoculation and thereafter declines, with symptom resolution within 10 days. There is no doubt that abundant virus propagation in the respiratory tract causes onset of influenza illness.1–3 Neuraminidase inhibitors (NAIs), such as oseltamivir phosphate, zanamivir hydrate and peramivir trihydrate, have been licensed as influenza antivirals in several countries. Many clinical trials in otherwise healthy influenza patients, where patients received antivirals at the peak or decline phase of virus shedding, showed that NAIs could reduce virus titres in nasopharyngeal wash by approximately 1 log, shortening the time to alleviation of influenza symptoms.4–7 These data

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
suggest that appropriate assessment of viral load reduction by influenza antivirals is important for estimating therapeutic outcomes in clinical settings. To predict and maximize antiviral efficacy for patients, it is necessary to determine the optimal clinical dosing regimens based on both preclinical and clinical data.\textsuperscript{8–10} To accomplish this, pharmacokinetic (PK) and pharmacodynamic (PD) studies have been conducted.\textsuperscript{11–13} For NAIs, both in vitro hollow-fibre infection system and in vivo infection models were used to establish PK/PD correlation with suppression of viral replication and with mouse survival, respectively.\textsuperscript{14–17} Another study investigated the in vivo viral load change for PB2 inhibitors in a lethal influenza A virus infection murine model.\textsuperscript{18}

The cap-dependent endonuclease (CEN) is an essential enzyme for virus transcription and resides in the N-terminal domain of the PA subunit of RNA polymerase. Baloxavir marboxil is a selective CEN inhibitor approved for the treatment of influenza A and B virus infections. The baloxavir marboxil prodrug is promptly and fully metabolized in humans into its active form, baloxavir acid,\textsuperscript{19} which inhibits replication of influenza A and B viruses in vitro and in vivo.\textsuperscript{20–24} In clinical trials, a single dose of baloxavir marboxil led to a profound decline in virus titres on nasopharyngeal swabs and faster alleviation of influenza symptoms in patients with uncomplicated infection.\textsuperscript{25}

The aim of the present study was to characterize the relationship between PK parameters and the antiviral activity of baloxavir acid based on virus titre reduction in the lungs of mice infected with influenza A virus, in order to predict and maximize the antiviral efficacy of baloxavir marboxil.

**Methods**

**Ethics**

All mouse studies were conducted under applicable laws and guidelines and with the approval of the Shionogi Animal Care and Use Committee (approval numbers: S10017D, S14072D, S14080D, S14083D, S16013D and S16129D).

**Compounds**

Baloxavir marboxil and baloxavir acid were from Shionogi & Co., Ltd, oseltamivir phosphate and zanamivir hydrate were from Sequoia Research Products Ltd (Pangbourne, UK) and laninamivir octanoate and favipiravir were from Toronto Research Chemicals Inc. (Toronto, Canada) and PharmaBlock Sciences, Inc. (Nanjing, China), respectively. Baloxavir marboxil and favipiravir were suspended using an agate mortar and pestle in 0.5% (w/v) methyl cellulose and 0.4% (w/v) carboxymethyl cellulose aqueous solution, respectively. Oseltamivir phosphate was dissolved in 0.5% (w/v) methyl cellulose, and zanamivir hydrate and laninamivir octanoate were dissolved in saline. Baloxavir acid was dissolved in 10% (w/v) Tween 80 and 0.5% (w/v) vinylpyrrolidone-vinyl acetate copolymer in sodium carbonate-sodium hydroxide buffer under heating and the pH was adjusted to ~9. For dosing, each solution or suspension was diluted with the same respective vehicle.

**Cells and viruses**

Madin–Darby canine kidney (MDCK) cells were obtained from the European Collection of Cell Cultures (Wiltshire, UK), A/WSN/33 (H1N1) and A/Osaka/129/2009 (H1N1pdm09) strains were obtained from the Osaka Prefectural Institute of Public Health and A/Hong Kong/8/68 (H3N2) and B/Hong Kong/5/72 strains were obtained from ATCC (Manassas, VA, USA). The A/WSN/33-NA/H274Y strain was prepared at Shionogi & Co. All viruses were propagated in MDCK cells and stored at $-80\,^\circ\mathrm{C}$ until use, and the infectious titres determined by standard TCID\textsubscript{50} assay. For measurement of lung virus titres, serial dilutions of lung homogenates were inoculated onto confluent MDCK cells as described previously.\textsuperscript{26} The presence of cytopathic effects was determined microscopically and virus titres were calculated as log\textsubscript{10} TCID\textsubscript{50}/mL. When no cytopathic effect was observed in the lowest dilution (10-fold), the titre of undetected virus was defined as 1.5 log\textsubscript{10} TCID\textsubscript{50}/mL.

**Animals**

Specific pathogen-free 6-week-old female BALB/c mice (Charles River Laboratories Japan, Inc., Yokahama, Japan) were used.

**Murine model construction**

Virus titres in the lungs of mice inoculated with A/WSN/33 at 0.25×, 0.5× or 1× LD\textsubscript{50} (five per group) were assessed over time to ascertain the time course of infection and to determine the optimal virus inoculation dose and timepoint for initiation of antiviral treatment.

**Antiviral studies in mice**

Mice (anaesthetized using a mixture of 1.6 mg/mL zolazepam, 1.6 mg/mL tiletamine and 1.9 mg/mL xylazine) were infected intranasally with a sub-lethal dose of influenza virus as follows: 100 TCID\textsubscript{50} for A/WSN/33, A/Hong Kong/8/68 and A/WSN/33-NA/H274Y infection; 400 TCID\textsubscript{50} for B/Hong Kong/5/72 infection; and 4300 TCID\textsubscript{50} for A/Osaka/129/2009 infection.

Five days after inoculation, A/WSN/33-infected mice were treated with baloxavir marboxil [0.5, 1.5, 5 or 50 mg/kg orally q12h; 10/group (Figure 3), and 5 mg/kg orally q12h; 15/group (Figure 2)], oseltamivir phosphate [5 or 50 eq mg/kg orally q12h; 10/group],\textsuperscript{27} laninamivir octanoate [1 or 3 mg/kg intranasally q24h; 15/group],\textsuperscript{28} zanamivir hydrate [10 mg/kg intranasally q12h; 15/group],\textsuperscript{29} favipiravir [50 or 150 mg/kg orally q12h; 15/group],\textsuperscript{30} or vehicle [0.5% (w/v) methyl cellulose in aqueous solution; 15/group (Figure 2) and 10/group (Figure 3)], for 1 day.

Mice infected with other types/subtypes of influenza viruses were treated at day 5 post-infection with baloxavir marboxil [0.5, 1.5, 5 or 50 mg/kg, q12h, for A/Hong Kong/8/68, B/Hong Kong/5/72 and A/WSN/33-NA/H274Y infection, and 0.5 or 5 mg/kg, q12h, for A/Osaka/129/2009 infection], oseltamivir phosphate [5 or 50 eq mg/kg, q12h, for A/Hong Kong/8/68 and B/Hong Kong/5/72 infection, and 5 eq mg/kg, q12h, for A/WSN/33-NA/H274Y and A/Osaka/129/2009 infection] or vehicle, for 1 day. Five A/Osaka/129/2009−, 10 A/Hong Kong/8/68−, 10 A/WSN/33-NA/H274Y− or 15 B/Hong Kong/5/72-infected mice were included per dose group.

To investigate the PK effects of baloxavir marboxil on viral load reduction, A/WSN/33-infected mice were treated at day 5 post-infection with subcutaneous (back of the neck) baloxavir acid as follows: 0.25, 0.5, 1, 2, 4 or 8 mg/kg, q24h; 0.125, 0.25, 0.5, 1, 2 or 4 mg/kg, q12h and 0.0625, 0.125, 0.25, 0.5, 1 or 2 mg/kg q6h (five per group), for 1 day.

After 24 h, mice were euthanized by cervical dislocation and virus titre in lung homogenates were determined. The Δlog\textsubscript{10} TCID\textsubscript{50}/mL value for each mouse was calculated by subtracting the mean virus titre in vehicle-treated mice from individual virus titres in the substance-treated mouse.

**PK in infected mice**

A/WSN/33-infected mice were treated orally with baloxavir marboxil (0.5, 1.5, 5, 15 or 50 mg/kg) and blood was taken at 0.5, 1, 2, 4, 6, 8, 10 or 12 h after dosing (three mice per group per timepoint). Another group of A/WSN/33-infected mice received subcutaneous (back of the neck) baloxavir acid (0.125, 0.5, 2 or 8 mg/kg) and blood was taken at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8 or 24 h after dosing at 0.125, 0.5 or 2 mg/kg or at 0.083, 0.333, 0.5, 1, 2, 4, 6, 8 or 24 h after dosing at 8 mg/kg (three mice per group per timepoint).
In vivo PK/PD analysis of baloxavir marboxil

Plasma concentrations of baloxavir acid and baloxavir marboxil were determined by LC–tandem MS. Plasma concentration data following single dosing for 0.125, 0.5, 2 and 8 mg/kg doses were averaged by dose and nominal time. Mean plasma concentrations at each sampling time and each dose level were used for the PK analysis. For oral administration of baloxavir marboxil, $C_{\text{max}}$, $t_{\text{max}}$, terminal elimination half-life ($t_{1/2}$), $AUC_{0–12}$ and $AUC_{0–\infty}$ were calculated by WinNonlin Version 6.21 (Certara USA Inc., Princeton, NJ, USA) based on a non-compartment model with uniform weighting. For subcutaneous baloxavir acid administration, $C_{\text{max}}$, plasma concentration at 24 h after initial dosing ($C_{24}$), plasma concentration at the end of the dosing interval ($C_i$), $AUC_{0–24}$ and $t_{\text{max}}$ to reach plasma concentration of 2, 10 or 50 ng/mL ($T_{250}$, $T_{250}$ or $T_{500}$, respectively) were estimated in the same manner. The same PK parameters for 0.0625, 0.25, 1 and 4 mg/kg doses (which were not administered to infected mice for PK evaluation) were mathematically scaled by extrapolation or interpolation based on the PK parameters in infected mice dosed at 0.125, 0.5, 2 and 8 mg/kg. Scaling was conducted as follows: each parameter’s value at the 0.0625 mg/kg dose was calculated as $2/3$ of the parameter’s value at the 0.125 mg/kg dose; similarly, values at the 0.25 mg/kg dose were calculated as $2/3 \times$ the value at the 0.125 mg/kg dose + $1/3 \times$ the value at the 0.5 mg/kg dose, values at 1 mg/kg were calculated as $2/3 \times$ the value at 0.5 mg/kg + $1/3 \times$ the value at 2 mg/kg and values at 4 mg/kg were calculated as $2/3 \times$ the value at 2 mg/kg + $1/3 \times$ the value at 8 mg/kg.

**PK/PD analysis**

To investigate the relationship between antiviral activity and PK parameters following subcutaneous baloxavir acid dosing in the A/WSN/33 infection model, the sigmoid $E_{\text{max}}$ model was applied to virus titre data derived from individual mice in the PD studies, and to the PK parameters for doses 0.125, 0.5, 2 and 8 mg/kg that were calculated from the observed mean plasma concentrations at each dose and timepoint, and to the PK parameters for 0.0625, 0.25, 1 and 4 mg/kg doses that were mathematically scaled in PK studies as described above. The dependent variable ($y$) was the virus titre ($\log_{10}$ TCID$_{50}$/mL) at 24 h after initial dosing and the independent variable ($x$) was each PK parameter: $y = E_0 - E_{\text{max}} \times x/(E_{\text{max}} + x)$, where $E_0$ is the baseline effect, $E_{\text{max}}$ is the maximum effect, $E_{50}$ reflects $50\%$ of the maximum effect and $\gamma$ is a slope parameter. The linear model $y = E_0 - E_{\text{max}} \times x$ was also applied, where $\beta$ is a regression coefficient. In this case, $AUC_{0–24}$, $C_{\text{max}}$, $C_{24}$ and $C_r$ were used as the logarithmic values and the other PK parameters as the anti-logarithm. Model fitness was evaluated by the coefficient of determination $R^2$ adjusted for degrees of freedom.

**Statistical analyses**

Differences in lung virus titres 24 h after initial dosing of baloxavir marboxil, other anti-influenza drugs (oseltamivir phosphate 5 eq mg/kg q12h, zanamivir hydrate 10 mg/kg q12h, laninamivir octanoate 1 mg/kg q24h and favipiravir 50 mg/kg q12h) and vehicle were analysed by pairwise comparison with the fixed-sequence procedure for multiple testing under a one-way analysis of variance (ANOVA) model. Exploratory comparison of virus titres with baloxavir marboxil, other anti-influenza drugs (oseltamivir phosphate 50 eq mg/kg q12h, laninamivir octanoate 3 mg/kg q24h and favipiravir 150 mg/kg q12h) and vehicle was performed using a one-way ANOVA model without multiplicity adjustment. To analyse differences in viral load reduction, Dunnett’s test was applied for comparing the differences in mean $\log_{10}$ TCID$_{50}$/mL values between baloxavir marboxil- and oseltamivir phosphate-treated groups.

Statistical analyses were performed using SAS version 9.2 for Windows (SAS Institute, Cary, NC, USA). Two-sided adjusted $P$ values below 0.05 were considered statistically significant.

**Results**

**Murine model of influenza virus infection**

A sub-lethal murine model was established by measuring virus titres in the lungs of mice inoculated with A/WSN/33 at 0.25×, 0.5× or 1× LD$_{50}$. In all groups, virus titres reached a mean ± SD of 6.03 ± 0.35 to 6.55 ± 0.22 $\log_{10}$ TCID$_{50}$/mL by day 2 post-infection. Virus titres remained at similar levels to day 5 and then declined (Figure 1). Up to day 5, mice receiving the 0.25× LD$_{50}$ infection dose did not show significant body weight loss (Figure S1, available as Supplementary data at JAC Online). Furthermore, all these mice survived at 14 days post-infection. Therefore, we selected the virus inoculation dose of 0.25× LD$_{50}$ (100 TCID$_{50}$) on day 0 for subsequent investigations, initiated the treatment with test substances on day 5 post-infection and evaluated virus titre reduction on day 6 post-infection.

**Antiviral activities of oral baloxavir marboxil in the murine model**

All antivirals tested in A/WSN/33-infected mice showed significant reductions in mean viral load compared with vehicle. Lung virus titres in mice receiving baloxavir marboxil 5 mg/kg, q12h, were significantly lower than for each NAI or favipiravir (Figures 2 and 3). The effect of baloxavir marboxil was dose dependent (Figure 3). Compared with the clinically equivalent or higher dose of oseltamivir phosphate, baloxavir marboxil ≥1.5 mg/kg, q12h, significantly reduced virus titres. In mice receiving baloxavir marboxil ≥15 mg/kg, q12h, virus titres declined by >3 $\log_{10}$ TCID$_{50}$/mL compared with vehicle and by 2 $\log_{10}$ TCID$_{50}$/mL compared with oseltamivir phosphate 5 or 50 eq mg/kg, q12h.

In mice infected with other influenza virus types/subtypes, including an NAI-resistant variant and the clinical H1N1pdm09 strain, virus titres were significantly lower with baloxavir marboxil 5 mg/kg, q12h, than with vehicle (data not shown), and treatment with baloxavir marboxil 15 mg/kg, q12h, exhibited a ≥100-fold influenza A virus titre reduction or ≥10-fold influenza B virus titre reduction compared with the clinically equivalent or
higher dose of oseltamivir phosphate (Figure 4). Of note, treatment with baloxavir marboxil 5 mg/kg, q12h, was sufficient to lead to 100-fold virus titre reduction in mice infected with the H1N1pdm09 strain.

**PK of baloxavir acid after oral baloxavir marboxil administration**

To further assess the dose-dependent efficacy of baloxavir marboxil, we measured plasma concentrations of baloxavir acid in A/WSN/33-infected mice. Baloxavir acid plasma exposure increased dose proportionally up to 15 mg/kg of oral baloxavir marboxil, whereas exposure after treatment with oral baloxavir marboxil 50 mg/kg was lower than expected (Figure 5 and Table S1). Additionally, \( C_{\text{max, AUC0–12}} \) and AUC\(_{0–\infty}\) increased dose proportionally between 0.5 and 15 mg/kg doses of baloxavir marboxil, whereas with 50 mg/kg these values were lower than expected (Table 1). Furthermore, \( C_{\text{max}} \) was reached at 0.5–2 h post-administration of baloxavir marboxil; plasma concentrations of baloxavir acid then declined with a \( t_{1/2\alpha} \) of 2.24–3.14 h. \( T_{\text{max}} \) following a baloxavir marboxil dose of 50 mg/kg was slightly longer than for other doses (Table 1). Baloxavir marboxil was undetectable in almost all infected mice (data not shown), suggesting rapid conversion into baloxavir acid.

**PK of baloxavir acid after subcutaneous administration of baloxavir acid**

Because linearity of baloxavir acid plasma exposure was not observed at higher doses of oral baloxavir marboxil (15–50 mg/kg), we evaluated subcutaneous administration of baloxavir acid at 0.125, 0.5, 2, and 8 mg/kg. Baloxavir acid plasma concentration increased dose proportionally from 0.125 to 8 mg/kg and with the 8 mg/kg dose was similar to or higher than that following oral administration of baloxavir marboxil 50 mg/kg. This suggests that subcutaneous administration of baloxavir acid solution was superior to oral baloxavir marboxil administration in mice in terms of dose-proportional increase in plasma baloxavir acid (Figure 6).

**Antiviral activities of subcutaneous baloxavir acid in the lungs of infected mice**

Following subcutaneous administration of baloxavir acid solution at doses between 0.0625 and 8 mg/kg q24h, q12h or q6h in A/WSN/33-infected mice, virus titres in all baloxavir acid-treated groups at 24 h post-treatment initiation were numerically lower than in groups treated with vehicle or oseltamivir phosphate 5 eq mg/kg, q12h (Table S2).
PK/PD analysis of baloxavir acid in infected mice

PK parameters for 0.125, 0.5, 2 and 8 mg/kg doses of subcutaneous baloxavir acid were calculated from the observed mean plasma concentrations at each dose and time, and 0.0625, 0.25, 1 and 4 mg/kg doses were mathematically scaled (Table S3), and correlation with the antiviral activity of baloxavir acid was assessed. First, the sigmoid E\textsubscript{max} model was applied (Figure S2).

The adjusted R\textsuperscript{2} of AUC\textsubscript{0–24}, C\textsubscript{max}, C\textsubscript{24}, C\textsubscript{s} and T\textsubscript{>50} was 0.395, 0.236, 0.581, 0.581 and 0.285, respectively, and was not calculated for T\textsubscript{>2} and T\textsubscript{>10} because model convergence was not achieved; the adjusted R\textsuperscript{2} values of C\textsubscript{24} and C\textsubscript{s} were therefore the largest among the PK parameters (Table 2). The linear model was then applied (Figure 7). The adjusted R\textsuperscript{2} of AUC\textsubscript{0–24}, C\textsubscript{max}, C\textsubscript{24}, C\textsubscript{s}, T\textsubscript{2}, T\textsubscript{>10} and T\textsubscript{>50} was 0.392, 0.241, 0.522, 0.527, 0.317, 0.508 and 0.285, respectively. AUC\textsubscript{0–24} and C\textsubscript{s} were therefore the largest among the PK parameters.

PK/PD analysis of baloxavir acid in infected mice

Table 1. PK parameters of baloxavir acid after oral administration of baloxavir marboxil in A/WSN/33 (H1N1) strain-infected mice

| Baloxavir marboxil dose (mg/kg) | C\textsubscript{max} (ng/mL) | T\textsubscript{max} (h) | t\textsubscript{1/2} (h)\textsuperscript{a} | AUC\textsubscript{0–∞} (ng·h/mL) | AUC\textsubscript{0–12} (ng·h/mL) |
|------------------------------|-----------------|-----------------|-------------------|-----------------|-----------------|
| 0.5                          | 5.05            | 1.00            | 2.24              | 22.7            | 22.0            |
| 1.5                          | 14.3            | 2.00            | 4.43              | 66.1            | 62.6            |
| 5                            | 45.7            | 5.30            | 6.90              | 252             | 252             |
| 15                           | 175             | 11.30           | 13.40             | 459             | 459             |
| 50                           | 284             | 15.40           | 21.80             | 1059            | 1059            |

\textsuperscript{a}0.5 mg/kg, t\textsubscript{1/2}=4–10 h; 1.5–50 mg/kg, t\textsubscript{1/2}=6–12 h.

Figure 4. Efficacy of baloxavir marboxil (BXM; 0.5–50 mg/kg, q12h) or oseltamivir phosphate (5 or 50 eq mg/kg) against multiple strains of influenza virus. Virus titres in lungs 24 h after initial antiviral dosing (6 days after influenza infection). Each bar represents the mean ± SD difference from the mean log\textsubscript{10} TCID\textsubscript{50}/mL in the vehicle group in 10 mice except for the experiment for A/Osaka/129/2009 (5 mice) and B/Hong Kong/5/72 (15 mice). Virus titres of the vehicle groups were as follows: A/WSN/33, 5.10±0.41 log\textsubscript{10} TCID\textsubscript{50}/mL; A/WSN/33-NA/H274Y, 4.95±0.41 log\textsubscript{10} TCID\textsubscript{50}/mL; A/Osaka/129/2009, 5.41±0.71 log\textsubscript{10} TCID\textsubscript{50}/mL; A/Hong Kong/8/68, 4.97±0.38 log\textsubscript{10} TCID\textsubscript{50}/mL; and B/Hong Kong/5/72, 3.92±0.35 log\textsubscript{10} TCID\textsubscript{50}/mL. *Adjusted P<0.01, **adjusted P<0.001 and ***adjusted P<0.0001 versus oseltamivir phosphate 5 eq mg/kg, q12h; and †adjusted P<0.05 and ††adjusted P<0.0001 versus oseltamivir phosphate 50 eq mg/kg, q12h (Dunnett’s test).

Figure 5. Plasma concentration of baloxavir acid (BXA) in infected mice following oral treatment with baloxavir marboxil at 0.5–50 mg/kg. The plasma concentration of BXA in A/WSN/33 (H1N1) strain-infected mice was measured at each timepoint. Data represent the mean ± SD of three mice. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
0.295, respectively. Cₙ again exhibited the largest adjusted $R^2$ (Table 3). These results indicate that Cₙ or C₂₄ correlated more strongly than did other PK parameters with virus titre reduction at 24 h after dosing with baloxavir acid in the murine infection model.

**Discussion**

In this study, we first determined the murine model of influenza virus infection for investigation of the in vivo efficacy and PK/PD profile of baloxavir acid. Although viral load reduction is a direct virological endpoint for patients treated with a viral replication inhibitor, this endpoint has not been previously applied to any PK/PD study of NAIs because the range of virus titre reduction was insufficient for precise PK/PD correlation, even when using supratherapeutic doses. Therefore, PK/PD analyses of NAIs have previously been based on survival rates of mice or clinical symptoms of infected ferrets. Here, we focused on the virological endpoint of rapid reduction of virus burden following baloxavir marboxil treatment; therefore, comparisons with PK/PD studies of NAI are limited. We used a sub-lethal murine model, in which treatment was initiated 5 days after virus inoculation followed by lung virus titre quantification at 24 h post-dosing. Virus titre at 5 days post-infection (6.29 ± 0.21 log₁₀ TCID₅₀/mL) in this model, just before the decline in virus titre, is similar to the baseline virus titre observed in otherwise healthy influenza patients (viral loads ranged from 5.56 ± 1.89 to 5.94 ± 1.69 log₁₀ TCID₅₀/mL). We demonstrated that replication of influenza A(H1N1), A(H1N1)pdm09, A(H3N2), type B or NAI-resistant A(H1N1) virus was more strongly suppressed by baloxavir marboxil at the dose of 5 mg/kg, q12h, than by oseltamivir phosphate, although a slightly different antiviral activity of baloxavir marboxil between type A and B was observed in this study and in our previous work. The inhibitory values for type A virus strains were 4- to 5-fold more potent in the yield-reduction assay and 6- to 12-fold more potent in

![Figure 6. Plasma concentration of baloxavir acid (BXA) in infected mice following subcutaneous administration of BXA at 0.125–8 mg/kg. The plasma concentration of BXA in A/WSN/33 (H1N1) strain-infected mice was measured at each timepoint. Data represent the mean ± SD of three mice. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.](image)

**Table 2. Analysis of PK parameters of baloxavir acid in the sigmoid $E_{\text{max}}$ model**

| PK parameter | Model parameter | Estimate | Standard error | 95% CI | $P$ | $R^2$ (adjusted $R^2$) |
|--------------|-----------------|----------|----------------|--------|-----|----------------------|
| AUC₀–₂₄ (ng·h/mL) | $E_0$ | 3.821 | 0.116 | 3.590, 4.052 | <0.0001 | 0.415 |
|               | $E_{\text{max}}$ | 1.091 | 0.170 | 0.752, 1.429 | <0.0001 | (0.395) |
|               | EC₅₀ | 431.596 | 81.757 | 269.068, 594.124 | <0.0001 | |
|               | $\gamma$ | 4.170 | 2.291 | −0.385, 8.725 | 0.0722 | |
|               | $E_0$ | 3.806 | 0.208 | 3.391, 4.220 | <0.0001 | 0.261 |
|               | $E_{\text{max}}$ | 1.022 | 0.333 | 0.360, 1.683 | 0.0029 | (0.236) |
|               | EC₅₀ | 42.528 | 14.034 | 14.629, 70.427 | 0.0032 | |
|               | $\gamma$ | 2.421 | 1.972 | −1.500, 6.342 | 0.2230 | |
| C₂₄ (ng/mL) | $E_0$ | 3.928 | 0.116 | 3.697, 4.159 | <0.0001 | 0.595 |
|               | $E_{\text{max}}$ | 1.499 | 0.206 | 1.090, 1.908 | <0.0001 | (0.581) |
|               | EC₅₀ | 4.767 | 1.047 | 2.687, 6.848 | <0.0001 | |
|               | $\gamma$ | 1.843 | 0.649 | 0.554, 3.133 | 0.0056 | |
| Cₙ (ng/mL) | $E_0$ | 3.958 | 0.126 | 3.707, 4.210 | <0.0001 | 0.595 |
|               | $E_{\text{max}}$ | 1.554 | 0.233 | 1.091, 2.016 | <0.0001 | (0.581) |
|               | EC₅₀ | 4.108 | 0.961 | 2.199, 6.018 | <0.0001 | |
|               | $\gamma$ | 1.697 | 0.604 | 0.498, 2.897 | 0.0061 | |
| T₅₀ (h) | $E_0$ | 3.588 | 0.094 | 3.403, 3.774 | <0.0001 | 0.309 |
|               | $E_{\text{max}}$ | 1.913 | 2.859 | −3.770, 7.596 | 0.5051 | (0.285) |
|               | EC₅₀ | 16.534 | 38.174 | −59.353, 92.421 | 0.6660 | |
|               | $\gamma$ | 1.324 | 1.438 | −1.534, 4.183 | 0.3597 | |

Adjusted $R^2$ is the coefficient of determination $R^2$ adjusted for degrees of freedom; $P$ value <0.05 considered statistically significant.
the plaque-reduction assay than values for type B virus strains. Baloxavir marboxil reduces the virus titre in mice in vivo according to the types of influenza virus, similar to the in vitro activity of baloxavir acid. These results validate the use of virus titre changes in the PK/PD analysis of baloxavir marboxil/baloxavir acid.

Consistent with the dose-proportional increase in plasma concentration and the PK parameters of baloxavir acid following oral baloxavir marboxil treatment, dose-dependent reduction in virus titres in the lungs of mice receiving baloxavir marboxil was observed. However, the dose-proportional increase in plasma baloxavir acid concentration was limited to baloxavir marboxil doses of 0.5–15 mg/kg, suggesting that the linearity of plasma exposure to baloxavir acid would not be exhibited at higher doses of oral baloxavir marboxil. Conversely, subcutaneous administration of baloxavir acid showed a dose-proportional increase in baloxavir acid exposure even at higher baloxavir acid doses; therefore, we applied subcutaneous baloxavir acid treatment for the PK/PD relationship analysis.

Our PK/PD analysis of PK parameters and virus titre reduction showed that $C_s$ best predicted the antiviral activity of baloxavir acid. A limitation of our PD analysis is that it only assessed the A/WSN/33 strain. Although $C_s$ was the best PK parameter predicting the virus titres, we presume that $C_s$ is different for other influenza strains. Therefore, the target $C_s$ was not defined from the EC$_{50}$ derived from the linear and sigmoidal models. As shown in Figure 4, the oral administration of baloxavir marboxil at 15 mg/kg twice daily decreased the virus titre in mice infected with A/WSN/33 (H1N1), A/Hong Kong/8/68 (H3N2) and B/Hong Kong/5/72 strains by 2.64, 2.16 and 0.97 log$_{10}$ TCID$_{50}$/mL, respectively, compared with oseltamivir phosphate at 5 eq mg/kg. In order to provide superior reduction of virus titres compared with oseltamivir, we explored a 1 log reduction compared with oseltamivir phosphate for both influenza A and B viruses; therefore, we defined the target $C_s$ value of baloxavir acid as more than 6.85 ng/mL, which was the plasma concentration obtained with oral baloxavir marboxil at a dose of 15 mg/kg, q12h (Table S1). In a recent non-clinical study in nude mice, daily administration with a
suboptimal dose of baloxavir marboxil (10 mg/kg, q24h) did not clear the virus from the respiratory organs.31 A possible reason for the lower antiviral activity may be a longer interval of drug administration (q24h) because the half-life of baloxavir acid in mouse plasma ranges from 2.24 to 3.14 h. As shown with multiple-dosing treatment,25–29 q12h administration raises $C_s$ for baloxavir acid and exhibits potent and sustained antiviral activity. These results support our findings that it is important to maintain an appropriate baloxavir acid concentration in mouse plasma to maximize the antiviral efficacy. In clinical trials, human PK data showed that single-dose oral baloxavir marboxil treatment resulted in a >10-fold longer half-life of baloxavir acid in plasma compared with that in mice and plasma concentrations of baloxavir acid exceeded and maintained the target plasma concentration for longer than 120 h.19,32 Phase 3 baloxavir marboxil studies clearly demonstrated that patients with uncomplicated influenza, including adults and adolescents, exhibited greater viral load reduction 24 h after single-dose oral baloxavir marboxil treatment than after placebo (3.5 log10 TCID50/mL reduction) or treatment with oseltamivir phosphate (2.0 log10 TCID50/mL reduction) and the significant antiviral activity of baloxavir marboxil was sustained for several days. A different antiviral response to baloxavir marboxil by type A and type B viruses was also observed in other clinical studies.33,34 We therefore believe that our mouse model replicates closely the influenza viral kinetics seen in humans. The model may have utility in future studies for evaluating residual virus burden following antiviral treatment and thus the potential for transmission.35

Symptom resolution was faster with baloxavir marboxil than placebo, but not oseltamivir phosphate, in type A virus infections.25,34 These clinical findings suggest that our PK/PD analysis based on virus titre reduction in the murine model could be useful in predicting potent viral load reduction in patients, but might be limited in predicting a shorter time to symptom resolution in otherwise healthy influenza patients. Treatment with antiviral agents may fail to directly reflect the symptom alleviation benefit for such patients because influenza illness is closely linked to host immune response. Differences in host responses between humans and mice might be considered in both virological and therapeutic endpoints in future non-clinical studies. A limitation of our study is that it is not feasible to take sequential blood samples from the same individual mice; therefore, PK parameters must be obtained from groups of animals for different doses to be applied in PK/PD analysis. Another limitation is the large difference in PK of baloxavir acid in plasma between humans and mice. Additionally, the effects of possible interactions between baloxavir acid and plasma proteins were not considered in our study. Regimens inmurine models mimicking the human PK of baloxavir acid are warranted for further assessment of baloxavir marboxil.

A previously reported PK/PD analysis based on in vivo virus titre reduction evaluated the use of a PB2 inhibitor in an apparently lethal influenza A virus infection model, with treatment administered 24 h post-infection when virus titres were still increasing.18 In contrast, our murine model was designed for infection at sub-lethal doses where severe host response, such as significant body weight loss, was not observed and for initiation of antiviral treatment immediately before the decline in virus titres. Indeed, none of the mice infected at 0.25× LD50 in our model died because of the infection and any associated weight loss was modest and rapidly reversible. In our model, oseltamivir phosphate showed 0.5–1 log10 reduction in virus titres compared with vehicle, consistent with the titre reduction observed in clinical studies in which virus titres were already decreasing at day 2 in otherwise healthy placebo-treated influenza patients.25,36

In summary, we demonstrated that oral treatment with baloxavir marboxil exhibited rapid and potent virus titre reduction regardless of type/subtype of seasonal influenza virus in the sub-lethal murine infection model. Furthermore, we showed that $C_s$ or $C_{s24}$ was the PK parameter that predicted the antiviral activity of baloxavir acid. To the best of our knowledge, this is the first report on influenza antivirals to describe the PK/PD correlation based on reduction in lung virus titres in a sub-lethal murine influenza model. Our findings suggest that this PK/PD model could be helpful in predicting and maximizing virological outcomes in clinical settings of baloxavir marboxil.

### Table 3. Analysis of PK parameters of baloxavir acid in the linear model

| PK parameter | Model parameter | Estimate | Standard error | 95% CI       | $P$  | $R^2$ (adjusted $R^2$) |
|--------------|-----------------|----------|----------------|--------------|------|-----------------------|
| AUC0–24 (ng-h/mL) | $E_0$ | 5.705 | 0.326 | 5.056, 6.354 | <0.0001 | 0.399     |
| | $\beta$ | 0.400 | 0.052 | 0.296, 0.504 | <0.0001 | (0.392) |
| $C_{max}$ (ng/mL) | $E_0$ | 4.542 | 0.248 | 4.050, 5.034 | <0.0001 | 0.249     |
| | $\beta$ | 0.335 | 0.062 | 0.212, 0.458 | <0.0001 | (0.241) |
| $C_{s24}$ (ng/mL) | $E_0$ | 3.624 | 0.066 | 3.493, 3.756 | <0.0001 | 0.527     |
| | $\beta$ | 0.303 | 0.031 | 0.242, 0.364 | <0.0001 | (0.522) |
| $C_s$ (ng/mL) | $E_0$ | 3.603 | 0.064 | 3.475, 3.731 | <0.0001 | 0.532     |
| | $\beta$ | 0.318 | 0.032 | 0.255, 0.381 | <0.0001 | (0.527) |
| $T_{s2}$ (h) | $E_0$ | 5.141 | 0.297 | 4.550, 5.732 | <0.0001 | 0.324     |
| | $\beta$ | 0.090 | 0.014 | 0.062, 0.117 | <0.0001 | (0.317) |
| $T_{s10}$ (h) | $E_0$ | 4.095 | 0.103 | 3.890, 4.301 | <0.0001 | 0.513     |
| | $\beta$ | 0.060 | 0.006 | 0.048, 0.072 | <0.0001 | (0.508) |
| $T_{s50}$ (h) | $E_0$ | 3.569 | 0.083 | 3.403, 3.734 | <0.0001 | 0.303     |
| | $\beta$ | 0.055 | 0.009 | 0.037, 0.072 | <0.0001 | (0.295) |

Adjusted $R^2$ is the coefficient of determination $R^2$ adjusted for degree of freedom; $P$ value <0.05 is considered statistically significant.
Acknowledgements

We thank: Tetsu Kase (Osaka Institute for Public Health, Japan) for generously providing laboratory and clinical strains; Takahiro Noda, Kaoru Baba and members of Shionogi TechnoAdvance Research, Co., Ltd (Osaka, Japan) for excellent technical assistance; and Shinya Omoto, Keita Fukao, Takeki Uehara, Masahiro Kinoshita and Toshinari Ochi (Shionogi & Co., Ltd, Osaka, Japan) for providing valuable suggestions and assistance in manuscript preparation.

Funding

This study was funded by Shionogi & Co., Ltd, Osaka, Japan. Editorial support for manuscript preparation was also funded by Shionogi & Co., Ltd.

Transparency declarations

All authors are employees of Shionogi & Co., Ltd, Osaka, Japan. The authors have no other conflict of interest. Editorial support for the preparation of this manuscript was provided by Adrienn Kis, PhD, of Highfield, Oxford, UK.

Supplementary data

Figures S1 and S2 and Tables S1 to S4 are available as Supplementary data at JAC Online.

References

1. Carrot F, Vergy E, Ferguson NM et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008; 167: 775–85.
2. Wright PF, Neumann G, Kawaoka Y. Orthomyxoviruses. In: Knipe DM, Howley PM, eds. Fields Virology. 5th edn. Lippincott Williams & Wilkins, 2007; 1691–740.
3. Taubenberger JK, Morens D. The pathology of influenza virus infection. Annu Rev Pathol Mech Dis 2008; 3: 499–522.
4. Treanor JJ, Hayden FG, Vroonan PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016–24.
5. Kohn S, Yen M-Y, Cheong H-J et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011; 55: 5267–76.
6. Kohn S, Kida H, Mizuguchi M et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010; 54: 4568–74.
7. Kohn S, Kida H, Mizuguchi M et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011; 55: 2803–12.
8. Schmidt S, Barbour A, Sahre M et al. PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol 2008; 8: 549–56.
9. Rayner CR, Bulik CC, Karmal MA et al. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. Antimicrob Agents Chemother 2013; 57: 3478–87.
10. Iyer GR, Liao S, Massarella J. Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers. AAPS PharmSci 2002; 4: E22.
11. Gupta P, Kamath AV, Park S et al. Preclinical pharmacokinetics of MHA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. MAbS 2016; 8: 991–7.
12. Katsumata K, Chono K, Kato K et al. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primerase inhibitor, in a murine model of herpes simplex virus infection. Antimicrob Agents Chemother 2013; 57: 1339–46.
13. Rouan M-C, Gevers T, Royman D et al. Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model. Antimicrob Agents Chemother 2010; 54: 4534–9.
14. McSharry JJ, Weng Q, Brown A et al. Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 2009; 53: 2375–81.
15. Brown AN, McSharry JJ, Weng Q et al. Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 2011; 55: 1740–6.
16. Kadama M, Yoshida R, Hasegawa T et al. The relationship between in vivo antiviral activity and pharmacokinetic parameters of peramivir in influenza virus infection model in mice. Antiviral Res 2014; 109: 110–5.
17. Drusano GL, Preston SL, Smee D et al. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob Agents Chemother 2001; 45: 2115–8.
18. Tsai AW, McNeil CF, Leeman JR et al. Novel ranking system for identifying efficacious anti-influenza virus PB2 inhibitors. Antimicrob Agents Chemother 2015; 59: 6007–16.
19. Kashimi H, Ishibashi T, Kawaguchi N et al. Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings. Clin Drug Invest 2018; 38: 1189–96.
20. Omoto S, Speranzini V, Hashimoto T et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep 2018; 8: 9633.
21. Noshi T, Kitano M, Taniguchi K et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res 2018; 160: 109–17.
22. Fukao J, Noshi T, Yamamoto A et al. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. Antimicrob Chemother 2019; 74: 654–62.
23. Fukao J, Ando Y, Noshi T et al. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. PLoS One 2019; 14: e0217307.
24. Taniguchi K, Ando Y, Nobori H et al. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Sci Rep 2019; 9: 3466.
25. Hayden FG, Sugaya N, Hirotsu N et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 2018; 379: 913–23.
26. Kitano M, Kodama M, Itoh Y et al. Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice. Antimicrob Agents Chemother 2013; 57: 2286–94.
27. Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 1845–50.
28. Kubo S, Tomozawa T, Kakuta M et al. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother 2010; 54: 1256–64.
29 Pizzorno A, Abed Y, Rheaume C et al. Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses. Antiviral Res 2014; 105: 54–8.

30 Kiso M, Takahashi K, Sakai-Tagawa Y et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 2010; 107: 882–7.

31 Kiso M, Yamayoshi S, Murakami J et al. Baloxavir marboxil treatment of nude mice infected with influenza A virus. J Infect Dis 2020; 221: 1699–702.

32 Koshimichi H, Tsuda Y, Ishibashi T et al. Population pharmacokinetic and exposure-response analyses of baloxavir marboxil in adults and adolescents including patients with influenza. J Pharm Sci 2019; 108: 1896–904.

33 Watanabe A, Ishida T, Hirotsu N et al. Baloxavir marboxil in Japanese patients with seasonal influenza: dose response and virus type/subtype outcomes from a randomized phase 2 study. Antiviral Res 2019; 163: 75–81.

34 Ison MG, Portsmouth S, Yoshida Y et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 2020; doi:10.1016/S1473-3099(20)30004-9.

35 Leo LY, Zhou J, Frise R et al. Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission. PLoS Pathog 2020; 16: e1008395.

36 Lee N, Chan PKS, Hui DSC et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200: 492–500.